Cargando...
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
We examined 6 different FMS-like tyrosine kinase-3 (FLT3) inhibitors (lestaurtinib, midostaurin, AC220, KW-2449, sorafenib, and sunitinib) for potency against mutant and wild-type FLT3, as well as for cytotoxic effect against a series of primary blast samples obtained from patients with acute myeloi...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
American Society of Hematology
2010
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2826764/ https://ncbi.nlm.nih.gov/pubmed/20007803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-09-242859 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|